(Q38611406)

4 September 2017

Anxiety in Patients with Schizophrenia: Epidemiology and Management (English)

1 reference

4 September 2017

0 references

2

1 reference

4 September 2017

Henk Temmingh

1

1 reference

4 September 2017

19 October 2015

1 reference

4 September 2017

1 reference

4 September 2017

29

1 reference

4 September 2017

10

1 reference

4 September 2017

819-832

1 reference

https://scigraph.springernature.com/pub.10.1007/s40263-015-0282-7

4 September 2017

0 references

cites work

Schizophrenia: lifetime co-morbidity in a community sample.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

Use of mental health services for the treatment of panic disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

Panic attacks in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

Anxiety comorbidity in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

Comorbidity patterns in routine psychiatric practice: is there evidence of underdetection and underdiagnosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

How prevalent are anxiety disorders in schizophrenia? A meta-analysis and critical review on a significant association

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

Prevalence and incidence studies of anxiety disorders: a systematic review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

Psychiatric comorbidities and schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

Social anxiety disorder in first-episode psychosis: incidence, phenomenology and relationship with paranoia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

Measuring anxiety in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

Anxiety symptoms in psychotic disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

Age-of-onset of schizophrenic and obsessive-compulsive symptoms in patients with schizo-obsessive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

Comparison of clinical characteristics, co-morbidity and pharmacotherapy in adolescent schizophrenia patients with and without obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

Impact of psychiatric comorbidity in individuals at Ultra High Risk of psychosis - Findings from the Longitudinal Youth at Risk Study (LYRIKS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

Predicting schizophrenia: findings from the Edinburgh High-Risk Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

Obsessive-Compulsive Disorder, Psychosis, and Bipolarity: A Longitudinal Cohort and Multigenerational Family Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

Obsessive-compulsive disorder as a risk factor for schizophrenia: a nationwide study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

Pathogenesis of schizophrenia: a psychopathological perspective.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

Paranoid delusional disorder follows social anxiety disorder in a long-term case series: evolutionary perspective.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

Comorbid depressive and anxiety disorders in 509 individuals with an at-risk mental state: impact on psychopathology and transition to psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

The impact of posttraumatic stress disorder on quality of life and health service utilization among veterans who have schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

Interpersonal trauma and posttraumatic stress disorder in patients with severe mental illness: demographic, clinical, and health correlates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

Service utilization among veterans with schizophrenia and a comorbid anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

Anxiety disorders in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

Quality of life in schizophrenia: contributions of anxiety and depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

Impact of panic attacks on quality of life among patients with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

Presence of obsessive compulsive symptoms in first-episode schizophrenia or related disorders is associated with subjective well-being and quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

Associations of obsessive-compulsive symptoms with clinical and neurocognitive features in schizophrenia according to stage of illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

Prevalence and clinical correlates of obsessive-compulsive disorder in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

The 5-year course of obsessive-compulsive symptoms and obsessive-compulsive disorder in first-episode schizophrenia and related disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

Predictors of switching antipsychotic medications in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

Prevalence and relationship to delusions and hallucinations of anxiety disorders in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

Severity of psychotic episodes in predicting concurrent depressive and anxiety features in acute phase schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

Stress reactivity of emotional and verbal speech content in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

Social anxiety disorder in recent onset schizophrenia spectrum disorders: The relation with symptomatology, anxiety, and social rank.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

Association between psychopathology and suicidal behavior in schizophrenia. A cross-sectional study of 509 participants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

Psychiatric comorbidity among adults with schizophrenia: a latent class analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

Awareness of illness and insight into obsessive-compulsive symptoms in schizophrenia patients with obsessive-compulsive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

Childhood trauma is associated with a specific admixture of affective, anxiety, and psychosis symptoms cutting across traditional diagnostic boundaries

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

The effect of obsessive-compulsive symptomatology on executive functions in schizophrenia: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

Stable cognitive deficits in schizophrenia patients with comorbid obsessive-compulsive symptoms: a 12-month longitudinal study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

Neuropsychological functions and visual contrast sensitivity in schizophrenia: the potential impact of comorbid posttraumatic stress disorder (PTSD)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

Reinterpreting comorbidity: a model-based approach to understanding and classifying psychopathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

How research on the meta-structure of psychopathology aids in understanding biological correlates of mood and anxiety disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

Disorders without borders: current and future directions in the meta-structure of mental disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

Substance use in a large sample of patients with schizophrenia or related disorders and co-morbid obsessive-compulsive symptoms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

Anxiety and substance use comorbidity among inpatients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

Increased Early Life Stress and Depressive Symptoms in Patients With Comorbid Substance Abuse and Schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

Emotion deficits in people with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

The emotional paradox: dissociation between explicit and implicit processing of emotional prosody in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

Facial emotion processing in schizophrenia: a meta-analysis of functional neuroimaging data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

Autism spectrum disorders and schizophrenia: meta-analysis of the neural correlates of social cognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

Exploring the nature of facial affect processing deficits in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

Dysregulation of arousal and amygdala-prefrontal systems in paranoid schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

1H-MR spectroscopy and gray matter volume of the anterior cingulate cortex in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

BDNF Val66Met polymorphism and anxiety/depression symptoms in schizophrenia in a Chinese Han population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

Imaging genomics applied to anxiety, stress response, and resiliency

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

Association of serotonin transporter gene (SLC6A4) polymorphisms with schizophrenia susceptibility and symptoms in a Chinese-Han population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

Serotonin 5-HT1A receptors as targets for agents to treat psychiatric disorders: rationale and current status of research.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

Investigational drugs for anxiety in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

An open study of buspirone augmentation of neuroleptics in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

Augmentation with pregabalin in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

Serum levels of brain-derived neurotrophic factor and cortisol to sulfate of dehydroepiandrosterone molar ratio associated with clinical response to L-theanine as augmentation of antipsychotic therapy in schizophrenia and schizoaffective disorder pa

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

L-theanine relieves positive, activation, and anxiety symptoms in patients with schizophrenia and schizoaffective disorder: an 8-week, randomized, double-blind, placebo-controlled, 2-center study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

Sniffing around oxytocin: review and meta-analyses of trials in healthy and clinical groups with implications for pharmacotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

Effects of Oxytocin on Neural Response to Facial Expressions in Patients with Schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

Cannabidiol in humans-the quest for therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

Alexithymia in schizophrenia: associations with neurocognition and emotional distress.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

No words for feelings: alexithymia in schizophrenia patients and first-degree relatives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

21 January 2018

2 references

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

21 January 2018

12 December 2020

Multicenter collaborative panic disorder severity scale

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

Generalized anxiety disorder: rethinking diagnosis and rating

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

The fear of others: a qualitative analysis of interpersonal threat in social phobia and paranoia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

Obsessive-compulsive disorder (OCD) with schizotypy vs. schizophrenia with OCD: diagnostic dilemmas and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

Obsessive-compulsive disorder in schizophrenia: clinical characteristics and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

Obsessive-compulsive symptoms in schizophrenia: implications for future psychiatric classifications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

Psychopathology and quality of life among patients with comorbidity between schizophrenia spectrum disorder and obsessive-compulsive disorder: no evidence for a "schizo-obsessive" subtype.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

Testing a model of the relationship between childhood sexual abuse and psychosis in a first-episode psychosis group: the role of hallucinations and delusions, posttraumatic intrusions, and selective attention.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

Dissociation mediates the relationship between childhood trauma and hallucination-proneness

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

A rating scale for drug-induced akathisia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

The assessment of anxiety states by rating

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

The development of a Clinician-Administered PTSD Scale

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

The positive and negative syndrome scale (PANSS) for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

A composite scale applied to evaluate anxiety in schizophrenic patients (SAES).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

Cognitive behaviour therapy for schizophrenia: relationship between anxiety symptoms and therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

Antipsychotic and anxiolytic properties of risperidone, haloperidol, and methotrimeprazine in schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

Review of atypical antipsychotics in anxiety

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

Efficacy of quetiapine for the treatment of schizophrenia: a combined analysis of three placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

Second-generation antipsychotics for anxiety disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

Quetiapine is effective against anxiety and depressive symptoms in long-term treatment of patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

Dose-response and comparative efficacy and tolerability of quetiapine across psychiatric disorders: a systematic review of the placebo-controlled monotherapy and add-on trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

Quetiapine versus other atypical antipsychotics for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

Atypical antipsychotic augmentation in SSRI treatment refractory obsessive-compulsive disorder: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

Aripiprazole for the treatment of schizophrenia with co-occurring social anxiety: an open-label cross-taper study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

Anxious-depressive symptoms in schizophrenia: a new treatment target for pharmacotherapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

Treatment of obsessive-compulsive symptoms in schizophrenic patients with clomipramine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

Obsessive and compulsive symptoms in schizophrenia: a randomized controlled trial with fluvoxamine and neuroleptics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

A double-blind, placebo-controlled trial of sertraline for depressive symptoms in patients with stable, chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

The emergence of social phobia during clozapine treatment and its response to fluoxetine augmentation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

Escitalopram in the treatment of patients with schizophrenia and obsessive-compulsive disorder: an open-label, prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

An open study of fluvoxamine augmentation of neuroleptics in schizophrenia with obsessive and compulsive symptoms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia. Part 3: Update 2015 Management of special circumstances: Depression, Suicidality, substance use disorders and pregnancy and lactatio

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

Meta-analysis of selective serotonin reuptake inhibitor-associated QTc prolongation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

A comparison of the risk of QT prolongation among SSRIs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

Sertraline treatment of major depression in patients with acute MI or unstable angina

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

QT interval prolongation related to psychoactive drug treatment: a comparison of monotherapy versus polytherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

Mirtazapine: a review of its use in major depression and other psychiatric disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

Low-dose mirtazapine: a new option in the treatment of antipsychotic-induced akathisia. A randomized, double-blind, placebo- and propranolol-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

Pregabalin: a review of its use in adults with generalized anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

Pregabalin's abuse potential: a mini review focusing on the pharmacological profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

Misuse and abuse of pregabalin and gabapentin: cause for concern?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

Benzodiazepine augmentation of antipsychotic drugs in schizophrenia: a meta-analysis and Cochrane review of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

Obsessive-compulsive symptoms in patients with schizophrenia: a naturalistic cross-sectional study comparing treatment with clozapine, olanzapine, risperidone, and no antipsychotics in 543 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

Pregabalin-Associated Increase of Clozapine Serum Levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

Treatment of depressive symptoms in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

D2 and D3 dopamine receptor affinity predicts effectiveness of antipsychotic drugs in obsessive-compulsive disorders: a metaregression analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40263-015-0282-7

Strange feelings: do amygdala abnormalities dysregulate the emotional brain in schizophrenia?

21 January 2018

1 reference

12 December 2020

Relationships between obsessive-compulsive symptomatology and severity of psychosis in schizophrenia: a systematic review and meta-analysis.

1 reference

12 December 2020

Augmentation with antidepressants in schizophrenia treatment: benefit or risk

1 reference

12 December 2020

The prognostic significance of obsessive-compulsive symptoms in schizophrenia

1 reference

12 December 2020

Depressive and anxiety symptoms in patients with schizophrenia and schizophreniform disorder.

1 reference

12 December 2020

Treatment of obsessive compulsive symptoms in schizophrenia with fluoxetine.

1 reference

12 December 2020

Treatment of affective disorders in cardiac disease

1 reference

12 December 2020

Prevalence and clinical characteristics of obsessive-compulsive disorder and obsessive compulsive symptoms in Afrikaner schizophrenia and schizoaffective disorder patients.

1 reference

12 December 2020

Do schizophrenic patients show a disjunctive relationship among expressive, experiential, and psychophysiological components of emotion?

1 reference

12 December 2020

Augmentation of antipsychotic drug action by azapirone 5-HT1A receptor partial agonists: a meta-analysis.

1 reference

12 December 2020

Alexithymia in schizophrenia: an exploratory study

1 reference

12 December 2020

Efficacy of typical and atypical antipsychotics for primary and comorbid anxiety symptoms or disorders: a review

1 reference

12 December 2020

Associations of social anxiety and self-esteem across six months for persons living with schizophrenia spectrum disorders

1 reference

12 December 2020

Meta-analysis of noradrenergic and specific serotonergic antidepressant use in schizophrenia

1 reference

12 December 2020

Clinical and neuropsychological profiles of obsessive-compulsive schizophrenia: a pilot study

1 reference

12 December 2020

Temporolimbic volume reductions in schizophrenia

1 reference

12 December 2020

Aripiprazole in schizophrenia patients with comorbid obsessive-compulsive symptoms: an open-label study of 15 patients

1 reference

12 December 2020

Obsessive and Compulsive Symptoms in Schizophrenia

1 reference

12 December 2020

Effective short-term treatment of generalized anxiety disorder with trifluoperazine.

1 reference

12 December 2020

Comparison of clinical characteristics and comorbidity in schizophrenia patients with and without obsessive-compulsive disorder: schizophrenic and OC symptoms in schizophrenia.

1 reference

12 December 2020

Psychopathologic Precursors and Sociodemographic Risk Factors for the Schizophrenia Syndrome

1 reference

12 December 2020

Social Anxiety Disorder Comorbid with Schizophrenia: The Importance of Screening for This Under recognized and Under treated Condition

1 reference

12 December 2020

Neuroimaging in anxiety disorders.

1 reference

12 December 2020

Fluvoxamine treatment of obsessive-compulsive symptoms in schizophrenic patients: an add-on open study.

1 reference

12 December 2020

Antidepressants for the negative symptoms of schizophrenia

1 reference

12 December 2020

10.1007/S40263-015-0282-7

Identifiers

DOI

1 reference

4 September 2017

1 reference

PubMed ID

26482261